Genomic Testing
FOUNDATIONACT®
- Cancer TypeSolid Tumor
- Sample TypePeripheral Whole Blood
- Results Expected2 weeks*
What is FoundationACT?
FoundationACT is a blood-based circulating tumor DNA (ctDNA) assay for solid tumors that identifies clinically relevant genomic alterations driving the growth of a patient's cancer. This liquid biopsy can help physicians identify treatment options by providing clinically actionable information relevant to diagnosis, risk-stratification, and prognosis. Test results provide information about potential targeted therapies and/or available clinical trials to better inform treatment decisions.
FoundationACT is validated to detect all classes of genomic alterations and to analyze more than 60 of the most commonly mutated genes in solid tumors using only a blood sample.
Overview
FoundationACT
>60
genes interrogated
99%
PPV†
99%
sensitivity‡
- A single assay that detects all 4 classes of genomic alterations required to comprehensively profile a tumor.
- Identification of resistance mutations or fusions in lung cancer§
- Can be integrated with FoundationOne results to give a more complete picture of the evolution of a patient’s tumor
- Requires only two 10mL tubes of blood
† 99% PPV for all alterations, calculated as a weighted average of the PPV for each class of alteration, with the weighting based upon the frequency with which each class is detected. The PPV for base substitutions, indels, rearrangements, and copy number variations, each independently, are 99.9%, 98.8%, 98.0%, and 97.6%, respectively.
‡ >99% sensitivity for base substitutions, indels, and rearrangements at ≥ 1% MAF. Sensitivity for base substitutions at >0.5% MAF is 98.9% and sensitivity for copy number variations is >95% when the tumor fraction is ≥ 20%.
§ Ou SI, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SM. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping Journal of Thoracic Oncology (2017)
Publications
FoundationACT has been validated to detect all four classes of genomic alterations.
Published Clinical Study
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer
Obtaining a metastatic tissue biopsy can be challenging, and analysis of circulating tumor DNA (ctDNA) from blood may provide a minimally invasive alternative.
Published Case Study
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
Emergence of the preexisting MET Y1230C likely confers resistance to crizotinib in this case of METex14-positive NSCLC. Existence of pretreatment MET Y1230C may eventually modulate the response of METex14-positive NSCLC to type I MET tyrosine kinase inhibitors. Noninvasive plasma-based ctDNA assays can provide a convenient method to detect resistance mutations in patients with previously known driver mutations.
Interested in learning more about how a Comprehensive Genomic Profiling test might help your patient? Our publications can help:
Order FoundationACT
We provide physicians with several options for ordering FoundationACT for patients including online, fax, and e-mail. Healthcare providers must first complete a test requisition form to start the process and can expect results typically within 2 weeks from the time a specimen is received.

Patients
FoundationACT is ordered by your healthcare provider. Our patient info kit has all the information you and your doctor need to discuss FoundationACT testing.
Patient Resources
Providers
FoundationACT can be ordered online, by fax, or by phone. Please review and complete the provider resources before ordering.
Questions? We’re here to help.
Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email and a representative will respond during regular business hours.
We have even more to offer.
Learn more about our other tests, FoundationFocus™ CDx BRCA, FoundationOne®, FoundationOne®Heme, or explore insights and trials or partnerships.
* Typical turnaround time from receipt of specimen is two weeks